On 23 April 2012, orphan designation (EU/3/12/964) was granted by the European Commission to Dafra Pharma International NV, Belgium, for oleylphosphocholine for the treatment of leishmaniasis.
The sponsorship was transferred to Oblita Therapeutics, Belgium in August 2016.
|Disease / condition||
Treatment of leishmaniasis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.